Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Convertible Debt came in at $1.0 billion in Q2 2026, down 1.51% YoY from $1.0 billion in Q2 2025, and little changed on a QoQ basis from $1.0 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 5 years of Convertible Debt data on file, last reported at $1.0 billion in Q2 2026.
- Quarterly Convertible Debt fell 1.51% year-over-year to $1.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 1.51% YoY) and the FY2025 annual result came in at $1.0 billion, down 1.64% from the prior year.
- Convertible Debt was little changed at $1.0 billion in Q2 2026, from $1.0 billion in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $1.0 billion in Q3 2025 to a low of $1.0 billion in Q4 2025.
- A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Convertible Debt.
- The widest YoY moves for Convertible Debt: up 1.62% in 2025, down 1.64% in 2025.
- Tracing ALNY's Convertible Debt over 5 years: stood at $1.0 billion in 2022, then increased by 0.38% to $1.0 billion in 2023, then rose by 0.38% to $1.0 billion in 2024, then retreated by 1.64% to $1.0 billion in 2025, then rose by 0.32% to $1.0 billion in 2026.
- The last three Convertible Debt figures came in at $1.0 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Bn |
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | 1.02 Bn |
| Sep 30, 2024 | 1.02 Bn |
| Jun 30, 2024 | 1.02 Bn |
| Mar 31, 2024 | 1.02 Bn |
| Dec 31, 2023 | 1.02 Bn |
| Sep 30, 2023 | 1.02 Bn |
| Jun 30, 2023 | 1.02 Bn |
| Mar 31, 2023 | 1.02 Bn |
| Dec 31, 2022 | 1.02 Bn |
| Sep 30, 2022 | 1.02 Bn |